» Articles » PMID: 38661126

Elucidating the Chain of Command: Our Current Understanding of Critical Target Genes for P53-mediated Tumor Suppression

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

encodes a transcription factor that is centrally-involved in several pathways, including the control of metabolism, the stress response, DNA repair, cell cycle arrest, senescence, programmed cell death, and others. Since the discovery of as the most frequently-mutated tumor suppressor gene in cancer over four decades ago, the field has focused on uncovering target genes of this transcription factor that are essential for tumor suppression. This search has been fraught with red herrings, however. Dozens of p53 target genes were discovered that had logical roles in tumor suppression, but subsequent data showed that most were not tumor suppressive, and were dispensable for p53-mediated tumor suppression. In this review, we focus on p53 transcriptional targets in two categories: (1) canonical targets like (p21) and (PUMA), which clearly play critical roles in p53-mediated cell cycle arrest/senescence and cell death, but which are not mutated in cancer, and for which knockout mice fail to develop spontaneous tumors; and (2) a smaller category of recently-described p53 target genes that are mutated in human cancer, and which appear to be critical for tumor suppression by p53. Interestingly, many of these genes encode proteins that control broad cellular pathways, like splicing and protein degradation, and several of them encode proteins that feed back to regulate p53. These include ZMAT3, GLS2, PADI4, ZBXW7, RFX7, and BTG2. The findings from these studies provide a more complex, but exciting, potential framework for understanding the role of p53 in tumor suppression.

Citing Articles

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).

Tornesello M Int J Mol Med. 2024; 55(1).

PMID: 39450536 PMC: 11554381. DOI: 10.3892/ijmm.2024.5448.


The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies.

Kansal R Genes (Basel). 2024; 15(7).

PMID: 39062641 PMC: 11276294. DOI: 10.3390/genes15070863.

References
1.
Tripathi V, Kaur E, Kharat S, Hussain M, Damodaran A, Kulshrestha S . Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor. J Biol Chem. 2019; 294(36):13224-13232. PMC: 6737220. DOI: 10.1074/jbc.AC119.008483. View

2.
Fischer B, Chelbi S, Guarda G . Regulatory Factor X 7 and its Potential Link to Lymphoid Cancers. Trends Cancer. 2020; 6(1):6-9. DOI: 10.1016/j.trecan.2019.11.001. View

3.
Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

4.
Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y . FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. Cell Rep. 2020; 30(2):497-509.e4. DOI: 10.1016/j.celrep.2019.12.032. View

5.
Bernard A, Boidot R, Vegran F . Alternative Splicing in Cancer and Immune Cells. Cancers (Basel). 2022; 14(7). PMC: 8996879. DOI: 10.3390/cancers14071726. View